Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Elicio Therapeutics (ELTX) Total Liabilities (2020 - 2026)

Elicio Therapeutics filings provide 4 years of Total Liabilities readings, the most recent being $15.8 million for Q4 2023.

  • On a quarterly basis, Total Liabilities rose 14.72% to $15.8 million in Q4 2023 year-over-year; TTM through Dec 2023 was $15.8 million, a 14.72% increase, with the full-year FY2023 number at $15.8 million, up 14.72% from a year prior.
  • Total Liabilities hit $15.8 million in Q4 2023 for Elicio Therapeutics, down from $17.7 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $137.8 million in Q4 2020 to a low of $2.1 million in Q1 2023.
  • Median Total Liabilities over the past 4 years was $16.7 million (2023), compared with a mean of $33.5 million.
  • Biggest five-year swings in Total Liabilities: crashed 89.11% in 2021 and later skyrocketed 59.38% in 2023.
  • Elicio Therapeutics' Total Liabilities stood at $137.8 million in 2020, then crashed by 89.11% to $15.0 million in 2021, then dropped by 8.38% to $13.7 million in 2022, then increased by 14.72% to $15.8 million in 2023.
  • The last three reported values for Total Liabilities were $15.8 million (Q4 2023), $17.7 million (Q3 2023), and $14.1 million (Q2 2023) per Business Quant data.